Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.

Chen TL, Estey EH, Othus M, Gardner KM, Markle LJ, Walter RB.

Leuk Lymphoma. 2013 Nov;54(11):2534-6. doi: 10.3109/10428194.2013.777836. Epub 2013 Mar 27. No abstract available.

PMID:
23432687
[PubMed - indexed for MEDLINE]
2.

Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.

Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ.

J Clin Oncol. 2000 May;18(9):1867-75.

PMID:
10784627
[PubMed - indexed for MEDLINE]
3.

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL.

Blood. 1999 Feb 1;93(3):787-95.

PMID:
9920827
[PubMed - indexed for MEDLINE]
Free Article
4.

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM.

Cancer. 1999 Jan 15;85(2):358-67.

PMID:
10023703
[PubMed - indexed for MEDLINE]
5.

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.

Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C.

Leukemia. 2001 May;15(5):764-71.

PMID:
11368437
[PubMed - indexed for MEDLINE]
6.

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA; Children's Cancer Group Study 2951.

J Clin Oncol. 2003 Aug 1;21(15):2940-7.

PMID:
12885813
[PubMed - indexed for MEDLINE]
7.

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.

Boyiadzis M, Redner RL, Raptis A, Hou JZ, Agha M, Foon KA.

Ann Hematol. 2011 Jun;90(6):733-5. doi: 10.1007/s00277-010-1076-0. Epub 2010 Sep 21. No abstract available.

PMID:
20857113
[PubMed - indexed for MEDLINE]
8.

Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.

Rowe JM, Mazza JJ, Hines JD, Cassileth PA, Oken MM, Bennett JM, Andersen J.

Haematol Blood Transfus. 1990;33:326-9. No abstract available.

PMID:
2182427
[PubMed - indexed for MEDLINE]
9.

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV.

Pediatr Blood Cancer. 2010 May;54(5):694-702. doi: 10.1002/pbc.22366.

PMID:
20209646
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia.

Björkholm M, Björnsdottir J, Stenke L, Grimfors G.

Oncology. 1990;47(2):112-4.

PMID:
2314823
[PubMed - indexed for MEDLINE]
11.

Treatment of relapsed and refractory acute myeloid leukemia in adults.

Lazzarino M, Morra E, Alessandrino EP, Merante S, Bernasconi P, Bonfichi M, Caldera D, Bernasconi C.

Bone Marrow Transplant. 1989 Jan;4 Suppl 1:121-3. Review. No abstract available.

PMID:
2653487
[PubMed - indexed for MEDLINE]
12.

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.

Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M.

J Clin Oncol. 1997 May;15(5):1796-802.

PMID:
9164187
[PubMed - indexed for MEDLINE]
13.

Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

Daenen S, van der Holt B, Verhoef GE, Löwenberg B, Wijermans PW, Huijgens PC, van Marwijk Kooy R, Schouten HC, Kramer MH, Ferrant A, van den Berg E, Steijaert MM, Verdonck LF, Sonneveld P.

Leuk Res. 2004 Oct;28(10):1057-67.

PMID:
15289018
[PubMed - indexed for MEDLINE]
14.

Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

Lee SS, Lee JH, Lee JH, Kim DY, Kim SH, Lim SN, Lee YS, Seol M, Ryu SG, Kang YA, Jang S, Park CJ, Chi HS, Yun SC, Lee KH.

Leuk Res. 2009 Apr;33(4):511-7. doi: 10.1016/j.leukres.2008.08.009. Epub 2008 Sep 25.

PMID:
18819710
[PubMed - indexed for MEDLINE]
15.

Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.

Lazzarino M, Morra E, Alessandrino EP, Orlandi E, Pagnucco G, Merante S, Bernasconi P, Inverardi D, Bonfichi M, Bernasconi C.

Eur J Haematol. 1989 Nov;43(5):411-6.

PMID:
2612614
[PubMed - indexed for MEDLINE]
16.

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.

Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W.

J Clin Oncol. 1988 Feb;6(2):213-7.

PMID:
3422260
[PubMed - indexed for MEDLINE]
17.

Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.

Knauf WU, Ho AD, Körbling M, Hunstein W.

Haematol Blood Transfus. 1990;33:314-5. No abstract available.

PMID:
1969834
[PubMed - indexed for MEDLINE]
18.

Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.

Ehninger G, Fackler-Schwalbe E, Freund M, Heil G, Henke M, Hoelzer D, Hoffmann R, Kurrle E, Link H, Lösch A, et al.

Haematol Blood Transfus. 1990;33:316-7. No abstract available.

PMID:
2182425
[PubMed - indexed for MEDLINE]
19.

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL.

J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14.

PMID:
18854573
[PubMed - indexed for MEDLINE]
20.

Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.

Ho AD, Lipp T, Ehninger G, Meyer P, Freund M, Hunstein W.

Cancer Treat Rep. 1986 Aug;70(8):1025-7.

PMID:
3460698
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk